GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...
We never left a feature untouched in our reviews of the best PDF editor. From OCR and eSignatures to cloud storage services, we’ve tested them all – so we know what makes the best choice for ...
We list the best PDF merger tools, to make it simple and easy to combine documents together into one file. We put the top tools to the test to see which makes for the best workflow. The easiest ...
Together with GSK, the Boston-based research team will focus on understanding how dysfunctional lung epithelial cells initiate and perpetuate the disease, including alveolar type 2 (AT2) cells ...
GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work of a team ...
GSK is also seeking damages to compensate for the alleged infringement as well as a “compulsory ongoing licensing fee” for the claimed technologies. “Moderna has reaped billions of dollars in revenue ...
Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...
Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA vaccine-delivery technology, the company said in a pair of federal lawsuits.
GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...
GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages.